Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody

Multiple Sclerosis Journal

Volumn 21, Issue 5, 2015, Pages 656-659

  Ikeda, Kensuke ^a   Kiyota, Naoki ^a   Kuroda, Hiroshi ^a   Sato, Douglas Kazutoshi ^a   Nishiyama, Shuhei ^b   Takahashi, Toshiyuki ^b   Misu, Tatsuro ^a   Nakashima, Ichiro ^a   Fujihara, Kazuo ^a   Aoki, Masashi ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

aquaporin 4; glial fibrillary acidic protein; myelin basic protein; myelin oligodendrocyte glycoprotein; Neuromyelitis optica

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; GLIAL FIBRILLARY ACIDIC PROTEIN; METHYLPREDNISOLONE; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY; PREDNISOLONE; UNCLASSIFIED DRUG; BLOCKING ANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NEUROPROTECTIVE AGENT; AQUAPORIN 4 ANTIBODY;

ADULT; ARTICLE; ASTROCYTOPATHY; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID ANALYSIS; CORTICOSTEROID THERAPY; DEMYELINATION; DISEASE MARKER; DRUG MEGADOSE; HUMAN; MALE; MYELITIS; MYELOOPTIC NEUROPATHY; URINARY URGENCY; ANTAGONISTS AND INHIBITORS; ASTROCYTE; COMPLICATION; DEMYELINATING DISEASE; IMMUNOLOGY; METABOLISM; NEUROMYELITIS OPTICA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; ANTIBODY DETECTION; BLURRED VISION; CELL DAMAGE; CONTRAST ENHANCEMENT; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DYSURIA; EXTENSIVE TRANSVERSE MYELITIS; EYE EXAMINATION; EYE PAIN; GAIT DISORDER; HYPERREFLEXIA; LIMIT OF DETECTION; NEUROLOGIC EXAMINATION; OPTIC NEURITIS; PARESTHESIA; SENSORY DYSFUNCTION; URETHRAL CATHETERIZATION; VISUAL ACUITY;

ADULT; ANTIBODIES, BLOCKING; ASTROCYTES; DEMYELINATING DISEASES; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METHYLPREDNISOLONE; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; MYELITIS, TRANSVERSE; NEUROMYELITIS OPTICA; NEUROPROTECTIVE AGENTS;

EID: 84952794298     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514551455     Document Type: Article

References (10)

1. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007 ; 6: 805-815
2. Sato DK, Nakashima I, Takahashi T, et al. Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders. Neurology. 2013 ; 80: 2210-2216
3. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009 ; 66: 630-643
4. Fujihara K, Misu T, Nakashima I, et al. Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. J Clin Exp Neuroimmunol. 2012 ; 3: 58-73
5. Takano R, Misu T, Takahashi T, et al. Astrocytic damage is far more severe than demyelination in NMO: A clinical CSF biomarker study. Neurology. 2010 ; 75: 208-216
6. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology. 2012 ; 79: 1273-1277
7. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014 ; 82: 474-481
8. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: A comparative study. JAMA Neurol. 2014 ;:
9. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006 ; 66: 1485-1489
10. Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflamm. 2011 ; 8: 184